Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development.
Vasseur D, Bigot L, Beshiri K, Flórez-Arango J, Facchinetti F, Hollebecque A, Tselikas L, Aldea M, Blanc-Durand F, Gazzah A, Planchard D, Lacroix L, Pata-Merci N, Nobre C, Da Silva A, Nicotra C, Ngo-Camus M, Braye F, Nikolaev SI, Michiels S, Jules-Clement G, Olaussen KA, André F, Scoazec JY, Barlesi F, Ponce S, Soria JC, Besse B, Loriot Y, Friboulet L. Vasseur D, et al. Among authors: besse b. Mol Cancer. 2024 Oct 4;23(1):221. doi: 10.1186/s12943-024-02134-4. Mol Cancer. 2024. PMID: 39363320 Free PMC article.
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L. Facchinetti F, et al. Among authors: besse b. Clin Cancer Res. 2016 Dec 15;22(24):5983-5991. doi: 10.1158/1078-0432.CCR-16-0917. Epub 2016 Jul 11. Clin Cancer Res. 2016. PMID: 27401242 Clinical Trial.
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.
Pailler E, Faugeroux V, Oulhen M, Mezquita L, Laporte M, Honoré A, Lecluse Y, Queffelec P, NgoCamus M, Nicotra C, Remon J, Lacroix L, Planchard D, Friboulet L, Besse B, Farace F. Pailler E, et al. Among authors: besse b. Clin Cancer Res. 2019 Nov 15;25(22):6671-6682. doi: 10.1158/1078-0432.CCR-19-1176. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439588
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: besse b. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer.
Facchinetti F, Lacroix L, Mezquita L, Scoazec JY, Loriot Y, Tselikas L, Gazzah A, Rouleau E, Adam J, Michiels S, Massard C, André F, Olaussen KA, Vassal G, Howarth K, Besse B, Soria JC, Friboulet L, Planchard D. Facchinetti F, et al. Among authors: besse b. Eur J Cancer. 2020 Jun;132:211-223. doi: 10.1016/j.ejca.2020.03.025. Epub 2020 May 6. Eur J Cancer. 2020. PMID: 32388065
Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors.
Menssouri N, Poiraudeau L, Helissey C, Bigot L, Sabio J, Ibrahim T, Pobel C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Chauchereau A, Blanc-Durand F, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, van de Wiel P, den Biezen E, Wesseling-Rozendaal Y, Ponce S, Michiels S, Massard C, Gautheret D, Barlesi F, André F, Besse B, Scoazec JY, Friboulet L, Fizazi K, Loriot Y. Menssouri N, et al. Among authors: besse b. Clin Cancer Res. 2023 Nov 1;29(21):4504-4517. doi: 10.1158/1078-0432.CCR-22-3736. Clin Cancer Res. 2023. PMID: 37364000
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez Arango JD, Guaitoli G, Mizuta H, Combarel D, Tselikas L, Michiels S, Nikolaev SI, Scoazec JY, Ponce-Aix S, Besse B, Olaussen KA, Loriot Y, Friboulet L. Facchinetti F, et al. Among authors: besse b. Cancer Discov. 2023 Sep 6;13(9):1998-2011. doi: 10.1158/2159-8290.CD-22-1441. Cancer Discov. 2023. PMID: 37377403 Free PMC article.
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A, Belcaid L, Palmieri LJ, Teysonneau D, Cousin S, Spalato-Ceruso M, Aldea M, Vasseur D, Alame M, Blouin L, Soubeyran I, Nicotra C, Ngocamus M, Hollebecque A, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: besse b. Mol Cancer. 2023 Nov 4;22(1):176. doi: 10.1186/s12943-023-01878-9. Mol Cancer. 2023. PMID: 37924050 Free PMC article.
Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
Bigot L, Sabio J, Poiraudeau L, Annereau M, Menssouri N, Helissey C, Déas O, Aglave M, Ibrahim T, Pobel C, Nobre C, Nicotra C, Ngo-Camus M, Lacroix L, Rouleau E, Tselikas L, Judde JG, Chauchereau A, Bernard-Tessier A, Patrikidou A, Naoun N, Flippot R, Colomba E, Fuerea A, Albiges L, Lavaud P, Massard C, Friboulet L, Fizazi K, Besse B, Scoazec JY, Loriot Y. Bigot L, et al. Among authors: besse b. Eur Urol Oncol. 2024 Jun;7(3):527-536. doi: 10.1016/j.euo.2023.10.011. Epub 2023 Oct 27. Eur Urol Oncol. 2024. PMID: 38433714
603 results